Mode
Text Size
Log in / Sign up

Critical review links ADMA levels to endothelial impairment in pregnant women with HIV and preeclampsia in sub-Saharan AfricaHigh ADMA Levels Link HIV And Preeclampsia Risks

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note gaps in understanding ADMA clinical effects in pregnant women with HIV and preeclampsia.

This critical review focuses on the role of ADMA on endothelial impairment in preeclampsia comorbid with HIV infection. The scope includes the PRMT-DDAH1-ADMA eNOS axis, DDAH gene polymorphism, L-arginine/ADMA ratios, and circulating levels of ADMA in women presenting with both conditions during pregnancy in sub-Saharan Africa. The authors compare HIV+PE cohorts against PE-only and HIV-only groups.

The analysis indicates that high ADMA levels, poor L-arginine/ADMA ratios, and DDAH gene polymorphism are present in HIV-associated preeclampsia. While initiation of ART has been observed to be correlated with the decrease in circulating levels of ADMA in non-pregnancy HIV cohorts, the specific clinical effect of this decrease during pregnancy remains unclear. The review highlights an association between inflammatory signaling, reactive oxygen species, and HIV infection, noting potential inhibition of DDAH1 activity.

The authors acknowledge that the role of these factors in women presenting with both conditions during pregnancy is not well understood. Limitations include uncertainty regarding the clinical effect of ADMA decrease in pregnancy and existing mechanistic, genetic, and clinical evidence gaps. The practice relevance lies in the potential development of biomarkers and focused, situation-specific interventions, though the evidence is not yet definitive for clinical application.

High ADMA Levels Link HIV And Preeclampsia Risks

Imagine a pregnant woman feeling dizzy and swollen. Her doctor finds high blood pressure and protein in her urine. This is preeclampsia. Now imagine she also lives with HIV. When these two conditions meet, the risks for her and her baby grow. Doctors have long studied these diseases separately. But what happens when they overlap? A new review explains the hidden link.

The Hidden Chemical Bridge

Both preeclampsia and HIV damage the lining of blood vessels. This damage is called endothelial impairment. A chemical called asymmetric dimethylarginine or ADMA causes this trouble. ADMA stops the body from making nitric oxide. Nitric oxide keeps blood vessels relaxed and open. Without it, vessels tighten up. This leads to high blood pressure and poor blood flow.

Many women in sub-Saharan Africa live with HIV. Pregnancy is common there too. These two conditions often happen together. Current treatments manage each disease alone. But they do not fully fix the combined damage to blood vessels. Understanding this link helps doctors protect mothers and babies better.

A Factory That Stops Working

Think of your blood vessels as a busy highway. Nitric oxide is the traffic light that keeps cars moving. ADMA is like a broken light that turns red constantly. Cars pile up. Traffic jams form. In the body, this means blood cannot reach organs properly. HIV infection creates inflammation and stress. This stress breaks down the enzymes that clean up ADMA. The result is too much ADMA in the blood.

Researchers looked at women with HIV only. They also studied women with preeclampsia only. Finally, they examined women with both conditions. They found high ADMA levels in all groups. But levels were highest in women with both diseases. Their bodies also had low ratios of healthy L-arginine to ADMA. This imbalance makes the problem worse.

This doesn't mean this treatment is available yet.

The Role Of HIV Proteins

HIV has proteins that cause trouble. Proteins like gp120 and Tat trigger inflammation. They also create reactive oxygen species. These are unstable molecules that cause oxidative stress. This stress damages the enzymes that remove ADMA. So ADMA builds up in the system. It blocks nitric oxide production. This cycle worsens the risk of preeclampsia.

Doctors need to know this link to help patients. In places with few resources, this knowledge is vital. It helps explain why some women get sick faster. It also points to new ways to test for risk. Measuring ADMA levels could help doctors spot trouble early. This allows for focused care before a crisis hits.

This review combined many studies. But some data came from small groups. We do not know exactly how antiretroviral therapy affects ADMA during pregnancy. More research is needed to confirm these findings. We also need to see if changing ADMA levels helps patients.

Scientists are working on new biomarkers. These are markers that show disease risk early. They want to find drugs that lower ADMA safely. This could prevent preeclampsia in high-risk women. Until then, doctors must monitor these patients closely. Regular check-ups remain the best defense. Future trials will show if targeting ADMA works.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Asymmetric dimethylarginine (ADMA) is an endogenous eNOS competitive inhibitor that plays a critical role in regulating the bioavailability and homeostasis of nitric oxide (NO) and vascularity. The conditions of both preeclampsia (PE) and HIV infection have their endothelial impairment as their basis, and their prevalence is very high in sub-Saharan Africa, as well as their frequent comorbidity during pregnancy. Elevated ADMA amount suppresses the NO synthesis, which stimulates vasoconstriction, oxidative stress, and inflammation in the vascular wall, which are pathogenic events in PE and cardiovascular risk in HIV. While ADMA has been examined in PE and HIV research separately, its role in women presenting with both conditions during pregnancy is not well understood. Therefore, we conducted a critical review to determine whether ADMA acts as a mechanistic bridge between the involvement of HIV-mediated immune activation, oxidative stress, and the antiretroviral therapy (ART)-induced vascular perturbations, and the endothelial dysfunction that is typical of PE. We evaluated the PRMT-DDAH1-ADMA eNOS axis, outlining the growing evidence that DDAH1 and DDAH2 are the main metabolic enzymes of ADMA, and that ADMA activity is extremely vulnerable to oxidative inactivation. We compared evidence, based on PE-only, HIV-only, and HIV+PE cohorts, and combined the current primary clinical research, which revealed high ADMA levels, poor L-arginine/ADMA ratios, and DDAH gene polymorphism in HIV-associated PE in women. These findings suggest that inflammatory signaling and reactive oxygen species are associated with HIV infection and can potentially inhibit the activity of DDAH1 and increase PRMT-mediated methylation, contributing to systematic accumulation of ADMA and a deficiency of NO during pregnancy. We also investigated how the proteins of HIV infection (gp120, Tat, and Nef) mediate the increase in endothelial activity and oxidative stress, and explained how these proteins may have an indirect effect on the regulation of ADMA via inflammatory and redox-sensitive pathways. Even though the initiation of ART has been observed to be correlated with the decrease in circulating levels of ADMA in non-pregnancy HIV cohorts, it is not clear what the clinical effect of this decrease in pregnancy is, namely, immune reconstitution, angiogenic imbalance, and PE susceptibility. Thus, filling in mechanistic, genetic, and clinical evidence, our study determines the gaps in learning about the ADMA–HIV–PE axis and measures whether the modulation of the L-arginine/ADMA ratio or DDAH1 activity is a plausible diagnostic or treatment option. We present that an understanding of this pathway is key to the development of biomarkers and in the development of focused, situation-specific interventions, where resources are scarce, and the burden of disease is increasing.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.